Business

Chinese OINDP developer CF PharmTech announced that it has completed a $50 million Series F financing round approximately six months after completing a $90 million financing round. Investors participating in the latest financing include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund, and Watson Investment, as well as existing investors Passion … [Read more...] about CF PharmTech raises additional $50 million

Tiziana Life Sciences has announced a new agreement with STC Biologics for manufacturing of its TZLS-501 inhaled anti-IL-6 receptor monoclonal antibody. The company said that it is also working with Sciarra Laboratories to develop a nebulizer for delivery of TZLS-501 for the treatment of COVID-19. In addition, Tiziana said that it had submitted a patent application … [Read more...] about Tiziana announces progress on development of TZLS-501 inhaled anti-IL-6R mAb for COVID-19

VistaGen Therapeutics has announced that it signed a deal giving EverInsight Therapeutics development and commercialization rights to Vistagen's PH94B aloradine nasal spray for anxiety disorders in China, South Korea, and a number of other Asian countries. EverInsight, funded by the CBC Group, is paying $5 million up front, plus a potential $172 million in milestone … [Read more...] about EverInsight Therapeutics gets Asian rights to VistaGen’s PH94B nasal spray

North Carolina-based Renovion said that it has raised $8.1 million in a Series A financing round for development of its ARINA-1 nebulized glutathione/bicarbonate/ascorbic acid formulation for the treatment of chronic lung diseases. ARINA-1, which is delivered via the PARI eFlow nebulizer system, has been granted orphan drug designation by the FDA for the treatment of … [Read more...] about Renovion raises $8.1 million for development of inhaled mucolytic

Tonix Pharmaceuticals has announced that it will acquire assets from Trigemina, Inc that include intranasal oxytocin for the treatment of migraine headaches. Trigemina had licensed the nasal spray, now called TNX-1900, from Stanford University, and Tonix will assume that license. Trigemina Chief Medical Officer Shashidar H. Kori said, “We are excited that Tonix … [Read more...] about Tonix Pharmaceuticals acquires intranasal oxytocin from Trigemina

Inhalation CDMO Vectura and inhaled drug developer Aerami Therapeutics (formerly Dance Biopharm) have signed an agreement for development of inhaled imatinib for the treatment of pulmonary arterial hypertension (PAH), the companies said. Aerami will pay nothing up front, but will make milestone payments and pay development fees and royalties on any sales. Aerami will … [Read more...] about Vectura and Aerami partner on development of inhaled imatinib for PAH

UCB said that it is paying $125 million up front, plus up to $145 million in potential milestone payments, to acquire Engage Therapeutics. Engage has a single candidate, Staccato inhaled alprazolam, which is in Phase 2 development for the treatment of epileptic seizures. Engage acquired Staccato alprazolam from Alexza in 2017, and UCB says that it will continue to … [Read more...] about UCB acquires Engage Therapeutics, Staccato alprazolam

Marinomed Biotech has announced that Fidia Farmaceutici will begin marketing Marinomed's Carragelose-based nasal sprays in Italy in Fall 2020, and Sanova Pharma has signed an agreement to launch the new Carravin nasal spray in Austria in 2021, subject to approval. The company's Carregelose products are already available in a number of European countries, as well as … [Read more...] about Marinomed announces upcoming launches of its nasal sprays in Italy and Austria